Medical Treatments

(asked on 23rd June 2021) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many NICE technology appraisals have been delayed as a result of operational challenges in 2021; and if he will place in the Library a list of the affected appraisals.


Answered by
Jo Churchill Portrait
Jo Churchill
Minister of State (Department for Work and Pensions)
This question was answered on 26th July 2021

The 19 topics listed as follows have been delayed as a result of operational challenges in 2021.

- Tuberous sclerosis complex (seizures) – cannabidiol;

- Waldenstrom's macroglobulinaemia – zanubrutinib;

- Head and neck cancer (untreated, metastatic squamous cell) - nivolumab (with ipilimumab);

- Breast cancer (triple negative) - pembrolizumab (neoadjuvant, with chemotherapy);

- Renal cell carcinoma (metastatic, untreated) - nivolumab (with cabozantinib);

- Multiple sclerosis (relapsing-remitting) - diroximel fumarate;

- Upadacitinib for treating active psoriatic arthritis after inadequate response to disease modifying anti-rheumatic drugs (DMARDs);

- Gastric cancer (resect) - pembrolizumab (with chemotherapy and surgery);

- Dermatitis (atopic, moderate, severe, aged 12 and over) – upadacitinib;

- Tralokinumab for treating moderate to severe atopic dermatitis;

- Dermatitis (atopic, moderate, severe, aged 12 and over) – abrocitinib;

- Cough (refractory, chronic) – gefapixant;

- Renal cell carcinoma - pembrolizumab (adjuvant);

- Polyps (nasal), rhinosinusitis (chronic, severe) – mepolizumab;

- Ulcerative colitis (moderate, severe) – ozanimod;

- Ankylosing spondylitis (active) – upadacitinib;

- Lung cancer (non-small-cell, resected) - atezolizumab (adjuvant);

- Ankylosing spondylitis (active) – tofacitinib; and

- Hepatocellular carcinoma (advanced, treated) - cabozantinib (review of technology appraisal 582).

Reticulating Splines